Consistently, flow cytometry analysis revealed that CCl4 treatment compromised the production of effector molecules by gut ILC2s, such as Areg, IL‐5, and IL‐13 (Figure 3L,M; Figure S4C,D, Supporting Information), which participate in the process of tissue repair in colitis.[8] Similarly, BDL surgery also disturbed the production of Areg, IL‐5, and IL‐13 by gut ILC2s (Figure S4E‐H, Supporting Information). The gene discussed is IL13; the disease is colitis.